These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 22882813)

  • 41. Abbreviated Goal Management Training Shows Preliminary Evidence as a Neurorehabilitation Tool for HIV-associated Neurocognitive Disorders among Substance Users.
    Casaletto KB; Moore DJ; Woods SP; Umlauf A; Scott JC; Heaton RK
    Clin Neuropsychol; 2016; 30(1):107-30. PubMed ID: 26753986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. AIDS and multiple sclerosis: neural and mental features.
    Morriss R; Schaerf F; Brandt J; McArthur J; Folstein M
    Acta Psychiatr Scand; 1992 May; 85(5):331-6. PubMed ID: 1605052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multitasking capacities in persons diagnosed with schizophrenia: a preliminary examination of their neurocognitive underpinnings and ability to predict real world functioning.
    Laloyaux J; Van der Linden M; Levaux MN; Mourad H; Pirri A; Bertrand H; Domken MA; Adam S; Larøi F
    Psychiatry Res; 2014 Jul; 217(3):163-70. PubMed ID: 24731876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevated neurobehavioral symptoms are associated with everyday functioning problems in chronic methamphetamine users.
    Cattie JE; Woods SP; Iudicello JE; Posada C; Grant I;
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):331-9. PubMed ID: 23037647
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multimodal assessment of driving performance in HIV infection.
    Marcotte TD; Wolfson T; Rosenthal TJ; Heaton RK; Gonzalez R; Ellis RJ; Grant I;
    Neurology; 2004 Oct; 63(8):1417-22. PubMed ID: 15505158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are MMSE and HDS-R neuropsychological tests adequate for screening HIV-associated neurocognitive disorders?
    Nakazato A; Tominaga D; Tasato D; Miyagi K; Nakamura H; Haranaga S; Higa F; Tateyama M; Fujita J
    J Infect Chemother; 2014 Mar; 20(3):217-9. PubMed ID: 24462448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of demographic factors on functional capacity and everyday functional outcomes in schizophrenia.
    Gould F; Bowie CR; Harvey PD
    J Clin Exp Neuropsychol; 2012; 34(5):467-75. PubMed ID: 22272559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of HIV-associated neuropsychological impairment on everyday functioning.
    Heaton RK; Marcotte TD; Mindt MR; Sadek J; Moore DJ; Bentley H; McCutchan JA; Reicks C; Grant I;
    J Int Neuropsychol Soc; 2004 May; 10(3):317-31. PubMed ID: 15147590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuropsychological performance in asymptomatic HIV infection.
    Bornstein RA; Nasrallah HA; Para MF; Whitacre CC; Rosenberger P; Fass RJ; Rice R
    J Neuropsychiatry Clin Neurosci; 1992; 4(4):386-94. PubMed ID: 1358300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study.
    Lawler K; Mosepele M; Ratcliffe S; Seloilwe E; Steele K; Nthobatsang R; Steenhoff A
    J Int AIDS Soc; 2010 Apr; 13():15. PubMed ID: 20406460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.
    Nakasujja N; Miyahara S; Evans S; Lee A; Musisi S; Katabira E; Robertson K; Ronald A; Clifford DB; Sacktor N
    Neurology; 2013 Jan; 80(2):196-202. PubMed ID: 23269596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cognitive impairment in HIV infection.
    Krikorian R; Wrobel AJ
    AIDS; 1991 Dec; 5(12):1501-7. PubMed ID: 1814332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteomics and metabolomics of HIV-associated neurocognitive disorders: A systematic review.
    Williams ME; Naudé PJW; van der Westhuizen FH
    J Neurochem; 2021 May; 157(3):429-449. PubMed ID: 33421125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determinants of risk-taking in HIV-associated neurocognitive disorders.
    Gomez D; Power C; Gill MJ; Fujiwara E
    Neuropsychology; 2017 Oct; 31(7):798-810. PubMed ID: 28358552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuropsychological effects of early HIV-1 infection: assessment and methodology.
    Ingraham LJ; Bridge TP; Janssen R; Stover E; Mirsky AF
    J Neuropsychiatry Clin Neurosci; 1990; 2(2):174-82. PubMed ID: 2136072
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurocognitive disorders in HIV-1 infection. HNRC Group. HIV Neurobehavioral Research Center.
    Grant I; Heaton RK; Atkinson JH
    Curr Top Microbiol Immunol; 1995; 202():11-32. PubMed ID: 7587358
    [No Abstract]   [Full Text] [Related]  

  • 57. Development of normative neuropsychological performance in Thailand for the assessment of HIV-associated neurocognitive disorders.
    Heaps J; Valcour V; Chalermchai T; Paul R; Rattanamanee S; Siangphoe U; Sithinamsuwan P; Chairangsaris P; Nidhinandana S; Tipsuk S; Suttichom D; Fletcher J; Shikuma C; Ananworanich J
    J Clin Exp Neuropsychol; 2013; 35(1):1-8. PubMed ID: 23113809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Script representation in patients with Alzheimer's disease.
    Allain P; Le Gall D; Foucher C; Etcharry-Bouyx F; Barré J; Dubas F; Berrut G
    Cortex; 2008 Mar; 44(3):294-304. PubMed ID: 18387558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apathy, depression, and cognitive performance in HIV-1 infection.
    Castellon SA; Hinkin CH; Wood S; Yarema KT
    J Neuropsychiatry Clin Neurosci; 1998; 10(3):320-9. PubMed ID: 9706540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disordered knowledge of action order in action disorganisation syndrome.
    Forde EM; Humphreys GW; Remoundou M
    Neurocase; 2004 Feb; 10(1):19-28. PubMed ID: 15849156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.